Effect of butylphthalide injection combined with citicoline tablets on acute cerebral infarction
刘芳 1尹园园 1姚远 1刘博 1王夏红 1张同歆
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 郑州市第二人民医院神经内科，郑州 450000
折叠
摘要
目的 探讨丁苯酞注射液联合胞磷胆碱片对急性脑梗死(ACI)患者美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)评分及血清相关细胞因子水平的影响。 方法 本研究为病例对照研究，选取2022年1月至2023年6月郑州市第二人民医院神经内科收治的80例ACI患者，男47例，女33例，年龄(60.90±4.70)岁，年龄范围为51～71岁，根据治疗方案不同将患者分为丁苯酞注射液组与联合组，每组40例。丁苯酞注射液组采用丁苯酞注射液治疗，联合组采用丁苯酞注射液联合胞磷胆碱片治疗。比较两组患者临床治疗效果、治疗前后的NIHSS、mRS评分、血脂水平[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇、甘油三酯]及血清相关细胞因子[C反应蛋白(CRP)、同型半胱氨酸(Hcy)、D-二聚体]水平。 结果 联合组患者临床治疗效果有效率[92.5%(37/40)]高于丁苯酞注射液组[75.0%(30/40)]，差异有统计学意义(P<0.05)。治疗后，联合组患者NIHSS评分[(3.42±0.59)分]、mRS评分[(1.22±0.24)分]均低于丁苯酞注射液组[(5.88±1.24)分、(2.03±0.31)分]；联合组患者HDL-C[(1.58±0.13)mmol/L]高于丁苯酞注射液组[(1.41±0.16)mmol/L]，LDL-C[(2.09±0.33)mmol/L]、总胆固醇[(3.25±0.46)mmol/L]、甘油三酯[(1.01±0.27)mmol/L]均低于丁苯酞注射液组[(3.15±0.37)mmol/L、(4.82±0.51)mmol/L、(1.58±0.31)mmol/L]；联合组患者CRP[(4.92±1.08)mg/L]、Hcy[(13.23±4.08)μmol/L]、D-二聚体[(131.95±12.18)μg/L]均低于丁苯酞注射液组[(7.11±1.63)mg/L、(19.79±5.24)μmol/L、(159.84±16.72)μg/L]，差异均有统计学意义(P<0.05)。 结论 丁苯酞注射液联合胞磷胆碱片可显著提高临床治疗效果，降低ACI患者NIHSS、mRS评分，改善体内血脂水平及炎症反应。 Objective To investigate the effect of butylphthalide injection combined with citicoline tablets on the National Institutes of Health Stroke Scale(NIHSS)and modified Rankin scale(mRS)scores and serum levels of related cytokines in patients with acute cerebral infarction(ACI). Methods This study was a case-control study, selected 80 patients with ACI of the department of Neurology in Zhengzhou Second Hospital from January 2022 to June 2023, there were 47 males and 33 females, aged(60.90±4.70)years old, ranging from 51 to 71 years old.The patients were divided into the butylphthalide injection group and the combination group according to different treatment plans, with 40 cases in each group.The butylphthalide injection group was treated with butylphthalide injection, while the combination group was treated with butylphthalide injection combined with citicoline tablets.The clinical efficacy of the two groups of patients was compared, as well as the NIHSS, mRS scores, blood lipid levels [high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), total cholesterol, triglycerides]and serum-related cytokines [C-reactive protein(CRP), homocysteine(Hcy), D-dimer(D-D)]levels before and after treatment. Results The clinical efficacy rate of the combined group [92.5%(37/40)]was higher than that of the butylphthalide injection group [75.0%(30/40)], and the difference was statistically significant(P<0.05).After treatment, the NIHSS score [(3.42±0.59)scores]and mRS score [(1.22±0.24)scores]of patients in the combined group were lower than those in the butylphthalide injection group [(5.88±1.24)scores and(2.03±0.31)scores] the HDL-C level [(1.58±0.13)mmol/L]of patients in the combined group was higher than that of the butylphthalide injection group [(1.41±0.16)mmol/L], while LDL-C level [(2.09±0.33)mmol/L], total cholesterol level [(3.25±0.46)mmol/L]and triglyceride level[(1.01±0.27)mmol/L]were lower than those in the butylphthalide injection group [(3.15±0.37)mmol/L, (4.82±0.51)mmol/L, (1.58±0.31)mmol/L] the CRP [(4.92±1.08)mg/L], Hcy [(13.23±4.08)μmol/L], D-D [(131.95±12.18)μg/L]and PTX3 [(1.74±0.28)μg/L]in the combined group were lower than those in the butylphthalide injection group [(7.11±1.63)mg/L, (19.79±5.24)μmol/L, (159.84±16.72)μg/L, (2.61±0.35)μg/L], and the differences were statistically significant(P<0.05). Conclusions Citicoline combined with butylphthalein can reduce the NIHSS and mRS scores in ACI patients, and improve blood flow parameters and lipid levels in middle cerebral artery.
Abstract
Objective To investigate the effect of butylphthalide injection combined with citicoline tablets on the National Institutes of Health Stroke Scale(NIHSS)and modified Rankin scale(mRS)scores and serum levels of related cytokines in patients with acute cerebral infarction(ACI). Methods This study was a case-control study, selected 80 patients with ACI of the department of Neurology in Zhengzhou Second Hospital from January 2022 to June 2023, there were 47 males and 33 females, aged(60.90±4.70)years old, ranging from 51 to 71 years old.The patients were divided into the butylphthalide injection group and the combination group according to different treatment plans, with 40 cases in each group.The butylphthalide injection group was treated with butylphthalide injection, while the combination group was treated with butylphthalide injection combined with citicoline tablets.The clinical efficacy of the two groups of patients was compared, as well as the NIHSS, mRS scores, blood lipid levels [high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), total cholesterol, triglycerides]and serum-related cytokines [C-reactive protein(CRP), homocysteine(Hcy), D-dimer(D-D)]levels before and after treatment. Results The clinical efficacy rate of the combined group [92.5%(37/40)]was higher than that of the butylphthalide injection group [75.0%(30/40)], and the difference was statistically significant(P<0.05).After treatment, the NIHSS score [(3.42±0.59)scores]and mRS score [(1.22±0.24)scores]of patients in the combined group were lower than those in the butylphthalide injection group [(5.88±1.24)scores and(2.03±0.31)scores] the HDL-C level [(1.58±0.13)mmol/L]of patients in the combined group was higher than that of the butylphthalide injection group [(1.41±0.16)mmol/L], while LDL-C level [(2.09±0.33)mmol/L], total cholesterol level [(3.25±0.46)mmol/L]and triglyceride level[(1.01±0.27)mmol/L]were lower than those in the butylphthalide injection group [(3.15±0.37)mmol/L, (4.82±0.51)mmol/L, (1.58±0.31)mmol/L] the CRP [(4.92±1.08)mg/L], Hcy [(13.23±4.08)μmol/L], D-D [(131.95±12.18)μg/L]and PTX3 [(1.74±0.28)μg/L]in the combined group were lower than those in the butylphthalide injection group [(7.11±1.63)mg/L, (19.79±5.24)μmol/L, (159.84±16.72)μg/L, (2.61±0.35)μg/L], and the differences were statistically significant(P<0.05). Conclusions Citicoline combined with butylphthalein can reduce the NIHSS and mRS scores in ACI patients, and improve blood flow parameters and lipid levels in middle cerebral artery.
万方数据